Business Description
MultiCell Technologies is a biopharmaceutical company focused on developing new treatments for neurological conditions, liver disease, cancer, and heart and vascular diseases. Its pipeline includes a Phase II drug candidate for multiple sclerosis-related fatigue, two cancer treatments using synthetic RNA technology, and a biodegradable stent designed for heart and vascular procedures. The company holds licensing agreements with Corning and Pfizer, and operates out of Woonsocket, Rhode Island.
